Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hairy cell leukemia.

L Savoie1, J B Johnston

  • 1CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba, Canada, R3E0V9.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Nucleoside analogs like 2"-deoxycoformycin (dCF) and 2-chlorodeoxyadenosine (CdA) are standard hairy cell leukemia (HCL) treatments, achieving remissions but with potential relapses. Modified CdA regimens show promise for improved safety and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.

Leukemia research·2021
Same author

Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

Current oncology (Toronto, Ont.)·2019
Same author

Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables.

Bone marrow transplantation·2018
Same author

In-vitro stability of porcine factor VIII (Hyate:C(®) ).

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.

Leukemia·2016
Same author

Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.

Current oncology (Toronto, Ont.)·2015
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Hairy cell leukemia (HCL) is typically treated with nucleoside analogs, 2"-deoxycoformycin (dCF) and 2-chlorodeoxyadenosine (CdA).
  • These agents induce complete remissions in most patients, but residual disease and relapses can occur.
  • Long-term follow-up data exist for dCF, showing significant relapse-free survival rates.

Purpose of the Study:

  • To review the efficacy and safety of nucleoside analog therapies for HCL.
  • To discuss alternative dosing and administration of CdA for improved outcomes.
  • To explore the role of other treatments like interferon-alfa and splenectomy.

Main Methods:

  • Review of existing literature on dCF and CdA treatment for HCL.
  • Analysis of response rates, relapse-free survival, and adverse events.

Related Experiment Videos

  • Comparison of different treatment regimens and agents.

    • Main Results:

    • dCF and CdA achieve high rates of morphologic complete remission in HCL.
    • Relapses occur but are often manageable with retreatment.
    • Modified CdA regimens (0.15 mg/kg weekly) may reduce febrile neutropenia risk.
    • Interferon-alfa shows inferior response rates but is an option for specific patient groups.
    • Splenectomy is rarely indicated but useful in select cases.

    Conclusions:

    • Nucleoside analogs remain the cornerstone of HCL therapy.
    • Optimized CdA administration offers a potentially safer and effective treatment option.
    • Interferon-alfa and other agents have roles in specific HCL patient populations.
    • Further research is needed for novel therapies like monoclonal antibodies.